Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
Epistemonikos ID: b929ab543f5ecc06c3d8e6a268a0486240eadeff
First added on: May 12, 2024